We will study the impact of new peptides involved in the regulation of food intake and metabolism in in vivo and ex vivo models. The clinical studies in normal subjects and in patients affected by simple obesity or by polycystic ovary syndrome (PCOS) (a syndrome characterized by hyperandrogenism, insulin resistance and hyperinsulinism frequently associated with obesity) will be performed at the Endocrine Unit headed by Prof. Renato Pasquali in which Dr. Pagotto is Assistent Professor. Each patient will undergo a psychological evaluation to identify eating disorders and to monitor the quality of life. A large data base containing hormonal and metabolic parameters, body composition and anthropometric indexes at basal condition and after different therapies will be generated. The role of ghrelin in pathological conditions as obesity or PCOS will be examined. Moreover, we will try to identify significant markers of HPA hyperactivity in abdominal obesity.
Finally, we will conduct clinical challenge with new compounds synthesized by enterprises in the same cohorts as above. Moreover, we will contribute to characterising the phenotype of mice ablated for cannabinoid receptor type 1 available in his lab by evaluating the expression pattern of the food intake-modulating neuropeptides, the metabolic and endocrine profile and the response to the in vivo administration of synthetic CB1 antagonists newly synthesized by any enterprise.